Background: Early detection of circulating tumor cells (CTCs) offers the possibility of improved outcome for patients with head and neck squamous cell cancer (HNSCC).
Methods: Patients with advanced-stage HNSCC (stage III/IV) were tested for CTCs using the CellSearch system (a registered trade name), which has been approved by the U.S. Food and Drug Administration (FDA) for monitoring CTCs in other cancers.
Results: CTCs were detected in 6 of 15 patients with advanced-stage HNSCC (range, 1-2 cells/7.5 mL of blood). CTCs were significantly associated with patients with lung nodules >1 cm (p = .04). There was also a suggestion of improved survival in the CTC-negative versus the CTC-positive patients (p = .11).
Conclusions: CTCs can be successfully isolated in patients with advanced-stage HNSCC using the CellSearch system. CTC detection may be important for prognosis, evaluating treatment outcome, and for determining efficacy of adjuvant treatments.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/hed.21941 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Silica-coated magnetic nanobeads in a flow enrichment target capture Halbach (FETCH) magnetic separation system for circulating tumor cell enrichment.
FEBS Lett
January 2025
Department of Medical Cell Biophysics, TechMed Center, Faculty of Science and Technology, University of Twente, Enschede, The Netherlands.
Article Synopsis
- Detecting circulating tumor cells (CTCs) is tough because they are present in low numbers and vary in characteristics, with traditional methods struggling for those with low EpCAM expression.
- This study introduces a new approach using silica-coated magnetic nanobeads with streptavidin for better CTC capture.
- The new method showed higher capture rates for specific cancer cell lines, especially those with low EpCAM expression, indicating its potential for improving CTC detection compared to existing commercial options.
A comprehensive review and meta-analysis of CTC isolation methods in breast cancer.
Crit Rev Oncol Hematol
November 2024
Institute of Molecular Theranostics, Sechenov First Moscow State Medical University, Moscow 119991, Russia; School of Biomedical Engineering, University of Technology Sydney, Sydney, NSW 2007, Australia.
The application of circulating tumor cells (CTCs) as diagnostic and prognostic markers in oncology is gaining increasing importance in clinical practice. Currently, various methods exist for detecting CTCs in patients' biological fluids. This systematic review aimed to compare the efficacy of different techniques for isolating and detecting CTCs from blood, against the FDA-cleared CellSearch® technology, in breast cancer patients.
View Article and Find Full Text PDFHER2(-Low) Expression on Circulating Tumor Cells and Corresponding Metastatic Tissue in Metastatic Breast Cancer.
Oncol Res Treat
November 2024
Heidelberg University Women's Hospital, Heidelberg, Germany.
Article Synopsis
- * This study aimed to evaluate the HER2 status of CTCs in mBC patients over three months of treatment, especially the implications for HER2-low cases, which are becoming increasingly relevant with new therapies involving antibody-drug conjugates (ADCs).
- * Results showed a discrepancy in HER2 status between CTCs and tumor tissues in 30.2% of patients, highlighting the challenges in diagnostic accuracy and the need for improved monitoring approaches in mBC treatment.
Blood Extracellular Vesicles Beyond Circulating Tumour Cells: A Valuable Risk Stratification Biomarker in High-Risk Non-Muscle-Invasive Bladder Cancer Patients.
Biomedicines
October 2024
Department of Molecular Medicine, "Sapienza" University of Rome, 00161 Rome, Italy.
Non-muscle-invasive bladder cancer (NMIBC) prognosis varies significantly due to the biological and clinical heterogeneity. High-risk stage T1-G3, comprising 15-20% of NMIBCs, involves the lamina propria and is associated with higher rates of recurrence, progression, and cancer-specific mortality. In the present study, we have evaluated the enumeration of tumour-derived extracellular vesicles (tdEVs) and circulating tumour cells (CTCs) in high-risk NMIBC patients and their correlation with survival outcomes such as time to progression (TTP), and cancer-specific survival (CSS).
View Article and Find Full Text PDFDevelopment and validation of a multi-marker liquid bead array assay for the simultaneous detection of and hotspot mutations in single circulating tumor cells (CTCs).
Heliyon
October 2024
Analysis of Circulating Tumor Cells Lab, Laboratory of Analytical Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, 15771 Athens, Greece.
Article Synopsis
- The study presents a new liquid bead array assay that detects specific mutations in circulating tumor cells (CTCs) from metastatic breast cancer (MBC) patients, which can help identify tumor progression and therapy resistance.
- The assay utilizes advanced techniques like enzymatic mutation enrichment and multiplex PCR, allowing for highly sensitive (0.1% mutation detection limit) and specific identification of mutations in single CTCs.
- Validation of the assay showed that it can analyze 96 single cells at once, making it both efficient and sample-conserving, thereby providing crucial insights into the genetic landscape of tumors.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!